SCHEMBL6129082

SCHEMBL6129082

O=[N+]([O-])N(O)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 2/20 0.49
CRHR2 Q13324 2/20 0.49
ALDH1A1 P00352 4/20 0.44
LMNA P02545 4/20 0.44
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
CPA1 P15085 3/20 0.41
ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL21219506 0.98 CRHBP (0.47) CRHBPCRHR2ALDH1A1LMNACYP1A2
SCHEMBL9404109 0.79 ALDH1A1 (0.52) CRHBPCRHR2ALDH1A1LMNACYP1A2
SCHEMBL9265192 0.78 CRHBP (0.47) CRHBPCRHR2ALDH1A1LMNACYP1A2
SCHEMBL8781469 0.78 CRHBP (0.47) CRHBPCRHR2ALDH1A1LMNACYP1A2
SCHEMBL2029473 0.78 CRHBP (0.51) CRHBPCRHR2ALDH1A1LMNASMN1; SMN2
SCHEMBL513918 0.77 ALDH1A1 (0.54) CRHBPCRHR2ALDH1A1LMNACYP1A2
SCHEMBL11745244 0.75 CRHBP (0.50) CRHBPCRHR2ALDH1A1LMNACYP1A2
SCHEMBL2325614 0.75 AOC3 (0.48) CRHBPCRHR2ALDH1A1LMNACYP1A2
Nitric Acid SCHEMBL27389059 0.73 ALDH1A1 (0.68) CRHBPCRHR2ALDH1A1LMNACYP1A2
SCHEMBL8930551 0.73 CRHBP (0.47) CRHBPCRHR2ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3521319-B1 METHOD FOR LIBERATING SUGAR CHAIN FROM GLYCOPROTEIN AIST (JP) 2024-01-10 EP claimed
US-20050282749-A1 Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes SANOS BIOSCIENCE A/S 2005-12-22 US disclosed
EP-1414486-A2 USE OF GLP-2 IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT IN BONE-RELATED AND NUTRITION-RELATED DISORDERS Osteometer Biotech AS (DK) 2004-05-06 EP disclosed
WO-2002024214-A2 USE OF GLP -2 IN COMBINATION WITH ANOTHER THERAPEUTIC AGENT IN BONE-RELATED AND NUTRITION-RELATED DISORDERS OSTEOMETER BIOTECH A/S (DK) 2002-03-28 WO disclosed
US-5112741-A Reaction with an amine ENZYMATICS, INC. (US) 1992-05-12 US disclosed